Refine
Year of publication
Language
- English (213)
Has Fulltext
- yes (213)
Is part of the Bibliography
- no (213)
Keywords
- BESIII (15)
- Branching fraction (9)
- e +-e − Experiments (9)
- Hadronic decays (5)
- Particle and Resonance Production (5)
- Branching fractions (4)
- Lepton colliders (4)
- Quarkonium (4)
- Charm Physics (3)
- Charmed mesons (3)
- Charmonium (3)
- Electroweak interaction (3)
- Exotics (3)
- Initial state radiation (3)
- Spectroscopy (3)
- e+-e− Experiments (3)
- Bhabha (2)
- Charm physics (2)
- Cross section (2)
- Electroweak Interaction (2)
- Hadronic cross section (2)
- Leptonic, semileptonic & radiative decays (2)
- Muon anomaly (2)
- Particle decays (2)
- Pion form factor (2)
- QCD (2)
- Angular distribution (1)
- Annihilation (1)
- BESIII detector (1)
- Born cross section measurement (1)
- C1 inhibitor (1)
- CP violation (1)
- Charmonium (-like) (1)
- Covariance matrix (1)
- Cross section measurements (1)
- D meson (1)
- D0 and D+ mesons (1)
- Dalitz decay (1)
- Dark photon (1)
- Dark sector (1)
- D⁰ meson (1)
- Electromagnetic amplitude (1)
- Electromagnetic form factor (1)
- Electromagnetic form factors (1)
- Experimental nuclear physics (1)
- Experimental particle physics (1)
- FOS: Physical sciences (1)
- Flavor changing neutral currents (1)
- Flavor symmetries (1)
- Flavour Physics (1)
- Form factors (1)
- Hadrons (1)
- High Energy Physics - Experiment (hep-ex) (1)
- Hyperons (1)
- Invisible decays (1)
- Neutrinos (1)
- Particle and resonance production (1)
- Particle phenomena (1)
- Phase (1)
- Polarization (1)
- Proton (1)
- Quantum chromodynamics (1)
- R value (1)
- Radiative decay (1)
- Rare decays (1)
- Semi-leptonic decays (1)
- Strong amplitude (1)
- Techniques Electromagnetic calorimeters (1)
- Triple quarkonia (1)
- Y (4260) (1)
- Y states (1)
- branching fractions (1)
- center-of-mass energy (1)
- charmed baryon (1)
- charmonium-like states (1)
- decay (1)
- decays (1)
- dimuon (1)
- diphoton (1)
- e+e − annihilation (1)
- e+e⁻ − Experiments (1)
- e+e− Experiments (1)
- e+e− annihilation (1)
- electron-positron collision (1)
- hadron spectroscopy (1)
- hadronic events (1)
- helicity amplitude analysis (1)
- hereditary angioedema (1)
- inclusive J/ψ decays (1)
- luminosity (1)
- number of J/ψ events (1)
- oral kallikrein inhibitor (1)
- prophylaxis (1)
- tetraquark (1)
- trigger efficiency (1)
- Λ+c baryon (1)
- Σ hyperon (1)
Using 10.1 × 109 J/ψ events produced by the Beijing Electron Positron Collider (BEPCII) at a center-of-mass energy √s = 3.097 GeV and collected with the BESIII detector, we present a search for the rare semi-leptonic decay J/ψ → D−e+νe + c.c. No excess of signal above background is observed, and an upper limit on the branching fraction ℬ(J/ψ → D−e+νe + c. c.) < 7.1 × 10−8 is obtained at 90% confidence level. This is an improvement of more than two orders of magnitude over the previous best limit.
Using 10.1 × 109 J/ψ events produced by the Beijing Electron Positron Collider (BEPCII) at a center-of-mass energy √s = 3.097 GeV and collected with the BESIII detector, we present a search for the rare semi-leptonic decay J/ψ → D−e+νe + c.c. No excess of signal above background is observed, and an upper limit on the branching fraction B(J/ψ → D−e +νe + c.c.) < 7.1 × 10−8 is obtained at 90% confidence level. This is an improvement of more than two orders of magnitude over the previous best limit.
Background: Effective inhibition of plasma kallikrein may have significant benefits for patients with hereditary angioedema due to deficiency of C1 inhibitor (C1‐INH‐HAE) by reducing the frequency of angioedema attacks. Avoralstat is a small molecule inhibitor of plasma kallikrein. This study (OPuS‐2) evaluated the efficacy and safety of prophylactic avoralstat 300 or 500 mg compared with placebo.
Methods: OPuS‐2 was a Phase 3, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Subjects were administered avoralstat 300 mg, avoralstat 500 mg, or placebo orally 3 times per day for 12 weeks. The primary efficacy endpoint was the angioedema attack rate based on adjudicator‐confirmed attacks.
Results: A total of 110 subjects were randomized and dosed. The least squares (LS) mean attack rates per week were 0.589, 0.675, and 0.593 for subjects receiving avoralstat 500 mg, avoralstat 300 mg, and placebo, respectively. Overall, 1 subject in each of the avoralstat groups and no subjects in the placebo group were attack‐free during the 84‐day treatment period. The LS mean duration of all confirmed attacks was 25.4, 29.4, and 31.4 hours for the avoralstat 500 mg, avoralstat 300 mg, and placebo groups, respectively. Using the Angioedema Quality of Life Questionnaire (AE‐QoL), improved QoL was observed for the avoralstat 500 mg group compared with placebo. Avoralstat was generally safe and well tolerated.
Conclusions: Although this study did not demonstrate efficacy of avoralstat in preventing angioedema attacks in C1‐INH‐HAE, it provided evidence of shortened angioedema episodes and improved QoL in the avoralstat 500 mg treatment group compared with placebo.